OBJECTIVES The aim of this study was to prospectively study and confirm the safety and efficacy of the Tryton Side Branch Stent in the treatment of coronary artery bifurcations involving large side branches (SBs).
B
ifurcation lesions are common and represent up to 20% of coronary lesions treated with percutaneous coronary intervention (PCI) (1, 2) . Bifurcation PCI is associated with a lower procedural success rate and a higher risk for adverse cardiac events (1, 2) . Data from multiple randomized controlled trials (RCTs) support a provisional 1-stent strategy over a systematic 2-stent strategy for bifurcation lesions (3) (4) (5) (6) (7) (8) (9) (10) (11) ; however, none of these studies was restricted to true bifurcation lesions involving large side branches (SBs).
The Tryton Pivotal RCT compared a dedicated bare-metal stent, designed to specifically secure and treat the bifurcation SB, with SB balloon angioplasty alone (provisional stenting) for the treatment of de novo true bifurcation lesions (12) . The intended study population was specified as patients with bifurcations involving large SBs ($2.5 mm by visual assessment); however, more than one-half of the enrolled lesions had diameters <2.25 mm by quantitative coronary angiography (QCA). This corresponds to a lesion <2.5 mm by visual assessment (12) Généreux et al.
characteristics of the patients are presented in Table 1 alongside the patients in the RCT who had SB diameters $2.25 mm by QCA. No significant differences were present in baseline characteristics, except for the prevalence of hypertension, which was significantly more common in the Tryton Confirmatory Study population compared with the Tryton SB group (but not the provisional group) of the RCT. In contrast to the RCT, which enrolled about 10% patients with non-true bifurcation lesions, all study patients had true bifurcation lesions ( Table 2) .
PROCEDURAL AND ANGIOGRAPHIC OUTCOMES.
Among the 133 enrolled patients, 132 (99.2%) received the study stent in the SB. Procedure, device, and lesion success rates were significantly higher with the Tryton stent in both the confirmatory study and the RCT compared with patients who had the provisional strategy (p < 0.001 for all) ( Table 3) . The need for additional stenting in the SB (bailout stenting) was required in 3 patients (2.3%; 1 dissection, 2 inadequate lesion coverage) who received the Tryton stent.
Procedures were on average longer and required more contrast and radiation when the Tryton stent strategy was used compared with the provisional 1-stent strategy ( Table 3) .
CLINICAL OUTCOMES. Clinical outcomes are summarized in Table 4 . No patient died during the procedure or within 30 days post-procedure. The primary endpoint, PPMI, occurred in 10.5% of the patients.
This was numerically lower than the provisional group in the Tryton Pivotal RCT (11.9%) (Figure 2 ).
The 95% confidence bounds did not extend beyond the pre-defined performance goal of 17.9%, and the noninferiority primary endpoint was met. Values are mean AE SD or n/N (%). *Tryton group in the confirmatory study versus Tryton group in the RCT. †Tryton group in the confirmatory study versus provisional group in the RCT.
CABG ¼ coronary artery bypass graft surgery; CVA ¼ cerebrovascular accident; PCI ¼ percutaneous coronary intervention; RCT ¼ randomized controlled trial; SB ¼ side branch; TIA ¼ transient ischemic attack. Branch Stent was associated with superior angiographic outcomes but failed to meet the pre-specified noninferiority criteria (12) . The high rate of the composite endpoint, target vessel failure, in the Tryton group was driven by a higher incidence of PPMI. A closer look at the data revealed that 59% of the patients had SBs that were smaller than the prespecified inclusion criteria. These patients had a disproportionally high incidence of procedure-related creatine kinase myocardial band elevation (13) . Patients with too small SBs assigned to the provisional (control) group were treated with appropriately sized angiography balloons, whereas those assigned to the Tryton group were treated with a stent mounted on an oversized balloon. A post hoc analysis of the intended study population (i.e., patients with SB diameters $2.25 mm) instead showed a numeric reduction in target vessel failure, which was within the pre-specified noninferiority margin, and superior angiographic outcomes at 9 months (13). The present study, which was designed in collaboration with the The Tryton Side Branch Stent is the first dedicated bifurcation stent to be compared head to head with the provisional technique in a multicenter RCT. The Tryton Pivotal RCT was also the largest RCT to exclusively studied bifurcation lesions (12) . The pivotal randomized trial (12) and its large SB post hoc analysis (13) , in conjunction with the present study, not only demonstrate the safety and efficacy of the Tryton Side Branch In-stent acute gain, mm 1.58 AE 0.43 1.53 AE 0.36 -0.30 -Values are n/N (%) or mean AE SD. *Medina classification 1,1,1; 1,0,1; or 0,1,1 as per angiographic core laboratory analysis. †Tryton group in the confirmatory study versus Tryton group in the RCT. ‡Tryton group in the confirmatory study versus provisional group in the RCT.
MLD ¼ minimal lumen diameter; RCT ¼ randomized controlled trial. STUDY LIMITATIONS. First, this study was not an RCT; however, the inclusion and exclusion criteria were identical to the recently conducted Tryton Values are n/N (%) or mean AE SD. *Achievement of final in-stent diameter <50% in side branch with assigned study device. †Achievement of final in-stent residual stenosis <30% (by quantitative coronary angiography) in side branch using the assigned study device without malfunction. ‡Achievement of final in-stent diameter of <50% (by quantitative coronary angiography) within the side branch. §Tryton group in the confirmatory study versus Tryton group in the RCT. kTryton group in the confirmatory study versus provisional group in the RCT.
RCT ¼ randomized controlled trial.
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Pivotal RCT. Therefore, a reliable optimal performance goal could be defined (on the basis of the group that was randomized to the provisional approach in the RCT). Second, only short lesions (<5 mm) with diameter stenoses >50% were enrolled.
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